Merck in Advanced Talks to Buy Seagen in Nearly US$ 40 Billion Deal
KONTAN.CO.ID - Drugmaker Merck & Co is in advanced talks to buy cancer-focused biotech company Seagen Inc in a deal that could be worth roughly US$ 40 billion or more. The Wall Street Journal reported on Wednesday.
The companies are discussing a price above US$ 200 a share for Seagen, the report said, citing people familiar with the matter.
